Drugs that, in some reports, have been weakly associated with torsades de pointes and/or QT prolongation but that are unlikely to be a risk for torsades de pointes when used in usual recommended dosages and in patients without other risk factors (e.g., concomitant QT prolonging drugs, bradycardia, electrolyte disturbances, congenital long QT syndrome, concomitant drugs that inhibit metabolism).
 
 
Clomipramine Anafranil® Tricyclic Antidepressant / depression
Amoxapine Asendin® Tricyclic Antidepressant / depression
Trimethoprim-Sulfa Bactrim® Antibiotic / bacterial infection
Citalopram Celexa® Anti-depressant / depression
Ciprofloxacin Cipro® Antibiotic / bacterial infection
Fluconazole Diflucan® Anti-fungal / fungal infection
Amitriptyline Elavil® Tricyclic Antidepressant / depression
Mexiletine Mexitil® Anti-arrhythmic / Abnormal heart rhythm
Ketoconazole Nizoral® Anti-fungal / fungal infection
Imipramine Norfranil® Tricyclic Antidepressant / depression
Nortriptyline Pamelor® Tricyclic Antidepressant / depression
Paroxetine Paxil® Anti-depressant / depression
Desipramine Pertofrane® Tricyclic Antidepressant / depression
Fluoxetine Prozac® Anti-depressant / depression
Galantamine Reminyl® Cholinesterase inhibitor / Dementia, Alzheimer's
Fluoxetine Sarafem® Anti-depressant / depression
Doxepin Sinequan® Tricyclic Antidepressant / depression
Itraconazole Sporanox® Anti-fungal / fungal infection
Trimethoprim-Sulfa Sulfa® Antibiotic / bacterial infection
Trimipramine Surmontil® Tricyclic Antidepressant / depression
Solifenacin VESIcare® muscarinic receptor anatagonist / treatment of overactive bladder
Protriptyline Vivactil® Tricyclic Antidepressant / depression
Sertraline Zoloft® Anti-depressant / depression
 
 
Revised: 03/01/2006


Source: www.QTdrugs.org

Drugs on the QT Drug Lists are reviewed on an ongoing basis to assure the evidence is still appropriate for their placement on their respective list. 

Close Window

 

 

Print

 

 

     

Arizona Center for Education and Research on Therapeutics
The Critical Path Institute

Tucson, Arizona and Rockville, Maryland

Funded in part by Agency for Healthcare Research and Quality grant 1 U18 HS10385

Disclaimer and Waiver
The information presented is intended solely for the purpose of providing general information about health related matters. It is not intended for any other purpose, including, but not limited to, medical or pharmaceutical advice and/or treatment, nor is it intended to substitute for the users' relationships with their own health care/pharmaceutical providers. To that extent, by continued use of this program, the user affirms the understanding of the purpose and releases The Critical Path Institute, The University of Arizona, State of Arizona and Arizona Board of Regents from any claims arising out of his/her use of the website.

 

Risk Group 2 Risk Group 3 Risk Group 1 Risk Group 1 Drug List 2 Risk Group 4